Study On Liprimar (Atorvastatin) In Patients With Coronary Heart Disease (CHD) And High Risk Of Cardiovascular Complications (LIGHT)

Viatris

Status: Completed

Conditions: Coronary Artery Disease; Cardiovascular Diseases

Treatments: Drug: Atorvastatin

Study type: Observational

Funder types: Industry

Identifiers

NCT00993915

A2581185

Details and patient eligibility

About

In which CHD patients with high risk of CV complications are different doses of LIPRIMAR used? For this purpose, data on hyperlipidemia will be elicited over and above the basic nosographic and demographic data, concomitant diseases and cardiovascular risk factor.

Enrollment: 687 patients

Sex: All

Ages: 18 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients, who eligible to sign informed consent;
• Patients with indications to lipid lowing therapy, according to local product document.
• Patients with CHD and high risk of CV complications (Diabetes Mellitus II, Myocardial Infarction, Heart Failure, Arterial Hypertension, ets) will be included into study;
• Patients with LDL levels: > 3,5 mmol/l

Exclusion criteria

• Individual intolerance of atorvastatin, in accordance to local product document.

Trial design

687 participants in 1 patient group

Main group

Description:

Newly diagnosed or known coronary artery disease and known dislipidemia and high risk of cardiovascular complications

Treatment:

Drug: Atorvastatin